1443.1: A Phase 1, open-label, dose-escalation study of SIRPα antagonist (BI 765063) with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors^1–3

Zoom

1. Champiat S, et al. ASCO 2021. Poster 2623; 2. Kotecki N, et al. ESMO 2021. Poster 983; 3. NCT03990233. https://clinicaltrials.gov/ct2/show/study/NCT03990233. Accessed September 2023.